EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Real‐World Comparative Effectiveness and Safety of Prasugrel Versus Ticagrelor After Acute Coronary Syndrome and Percutaneous Coronary Intervention

Munaza Riaz, Dominick J. Angiolillo, Craig R. Lee, Larisa H. Cavallari

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026-12 · 46 (12)

DOI: 10.1002/phar.70218 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Study Objective To compare the real‐world effectiveness and safety of prasugrel versus ticagrelor among patients with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI) in the United States. Design Retrospective new‐user cohort study. Data Source MarketScan Research Databases, 2017–2023. Patients Patients aged 18 years or older with ACS and PCI initiated on either prasugrel or ticagrelor were identified using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD‐10‐CM) diagnosis codes and prescription records. The prescription fill date was assigned as the index date. Patients were required to have continuous enrollment in their health care plan for 1 year prior to and including the index date. Measurements and Main Results Stabilized inverse probability treatment weighting was applied to balance baseline characteristics between treatment groups. Cox proportional hazards models with adherence adjustment were used to estimate 1 year risk of major adverse cardiovascular events (MACE, composite of myocardial infarction [MI], ischemic stroke, or stent thrombosis), bleeding events, and individual MACE components. The study included 6662 prasugrel‐treated and 25,452 ticagrelor‐treated patients. Prasugrel was associated with a lower risk of MACE (3.83 vs. 5.61 events per 100 person‐years; adjusted hazard ratio [aHR] 0.72, 95% confidence interval [CI] 0.65–0.92) and MI (3.43 vs. 4.73 events per 100 person‐years; aHR 0.80, 95% CI 0.66–0.97) compared with ticagrelor, respectively. Bleeding risk did not differ between prasugrel versus ticagrelor (2.85 vs. 3.89 events per 100 person‐years, respectively; aHR 0.92, 95% CI 0.74–1.13). Sensitivity analyses restricted to patients with high medication adherence and without contraindications to prasugrel showed similar results. Conclusion Among commercially insured US patients with ACS undergoing PCI, prasugrel was associated with a lower risk of ischemic cardiovascular events compared with ticagrelor, without an increase in bleeding risk, including in patients with high medication adherence. These findings provide contemporary real‐world evidence supporting the preferential use of prasugrel over ticagrelor following ACS and PCI in appropriately selected patients.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →